Fact Sheet: President Donald J. Trump is Accelerating Medical Treatments for Serious Mental Illness
Fact sheetRegulation easedPublished 04/18Open the original
Summary
President Trump orders the FDA to give National Priority Vouchers to psychedelic drugs with Breakthrough Therapy designation for serious mental illness and to create an access pathway for investigational psychedelics, with HHS allocating $50 million through ARPA-H to match state research investments.
By industry
- Healthcare & Drug Pricing1 trading day−1.0%p15 stocks5 trading days−2.6%p15 stocks20 trading days−4.1%p15 stocks
“provide Commissioner’s National Priority Vouchers to appropriate psychedelic drugs”
Day by day after the announcement
| Day | Healthcare & Drug Pricing stocks | S&P 500 |
|---|---|---|
| 26/04/17 | 0.0% | 0.0% |
| 26/04/20 | −1.1% | −0.1% |
| 26/04/21 | −1.7% | −0.5% |
| 26/04/22 | −2.2% | +0.0% |
| 26/04/23 | −0.9% | −0.1% |
| 26/04/24 | −2.1% | +0.5% |
| 26/04/27 | −2.2% | +0.8% |
| 26/04/28 | −1.3% | +0.3% |
| 26/04/29 | −0.7% | +0.4% |
| 26/04/30 | +0.3% | +1.4% |
| 26/05/01 | −0.7% | +1.3% |
| 26/05/04 | −0.8% | +1.1% |
| 26/05/05 | −1.0% | +2.3% |
| 26/05/06 | −1.8% | +3.2% |
| 26/05/07 | −2.1% | +2.9% |
| 26/05/08 | −2.2% | +3.9% |
| 26/05/11 | −1.8% | +4.1% |
| 26/05/12 | +0.1% | +3.8% |
| 26/05/13 | +1.0% | +4.7% |
| 26/05/14 | +1.1% | +5.3% |
| 26/05/15 | −0.2% | +3.9% |
Korean stocks in these industries
- Samsung Biologics 207940
- Celltrion 068270
- SK Biopharmaceuticals 326030
Trades in these industries around the announcement
Members' and insiders' trades in the industries' stocks, 30 days before to 30 days after.
- Alan Armstrong
BuyUnitedhealth Group
BuyUnitedhealth Group
UNH
$15K–$50K
Self
$15K–$50K
Reported 07/21
Traded 03/27
- Alan Armstrong
Full saleAmgen
Full saleAmgen
AMGN
$15K–$50K
Self
$15K–$50K
Reported 07/21
Traded 03/27
- Alan Armstrong
Full salePfizer
Full salePfizer
PFE
$50K–$100K
Self
$50K–$100K
Reported 07/21
Traded 03/24
- Lilly Endowment
SellELI Lilly
SellELI Lilly
LLY
$13.6M
13,620 sh
$13.6M
Filed 05/07
Traded 05/06
- Alan Armstrong
BuyAbbVie
BuyAbbVie
ABBV
$15K–$50K
Self
$15K–$50K
Reported 07/21
Traded 03/27
- Alan Armstrong
BuyJohnson & Johnson
BuyJohnson & Johnson
JNJ
$15K–$50K
Self
$15K–$50K
Reported 07/21
Traded 03/27
- Alan Armstrong
Full saleMerck
Full saleMerck
MRK
$15K–$50K
Self
$15K–$50K
Reported 07/21
Traded 03/27
- Alan Armstrong
Full saleELI Lilly
Full saleELI Lilly
LLY
$1K–$15K
Self
$1K–$15K
Reported 07/21
Traded 03/27
- Alan Armstrong
BuyMcKesson
BuyMcKesson
MCK
$1K–$15K
Self
$1K–$15K
Reported 07/21
Traded 03/27
- Alan Armstrong
BuyGilead Sciences
BuyGilead Sciences
GILD
$1K–$15K
Self
$1K–$15K
Reported 07/21
Traded 03/27
- Alan Armstrong
BuyJohnson & Johnson
BuyJohnson & Johnson
JNJ
$1K–$15K
Self
$1K–$15K
Reported 07/21
Traded 03/30
- Alan Armstrong
BuyElevance Health
BuyElevance Health
ELV
$1K–$15K
Self
$1K–$15K
Reported 07/21
Traded 03/27
- Patrick Hugh Conway
SellUnitedhealth Group
SellUnitedhealth Group
UNH
$284K
800 sh
$284K
Filed 04/27
Traded 04/23
- Lilly Endowment
SellELI Lilly
SellELI Lilly
LLY
$2.2M
2,208 sh
$2.2M
Filed 05/07
Traded 05/06
- David V. Elkins
SellBristol Myers Squibb
SellBristol Myers Squibb
BMY
$1.6M
25,519 sh
$1.6M
Filed 04/02
Traded 04/01
- Daniel Patrick O'Day
Sell10b5-1 planGilead Sciences
Sell10b5-1 planGilead Sciences
GILD
$1.4M
10,000 sh
$1.4M
Filed 03/30
Traded 03/27
- David Cordani
Sell10b5-1 planCigna Group
Sell10b5-1 planCigna Group
CI
$11.9M
41,099 sh
$11.9M
Filed 05/14
Traded 05/12
- David Cordani
Sell10b5-1 planCigna Group
Sell10b5-1 planCigna Group
CI
$11.4M
38,487 sh
$11.4M
Filed 05/14
Traded 05/12
- David Cordani
Sell10b5-1 planCigna Group
Sell10b5-1 planCigna Group
CI
$10.3M
34,641 sh
$10.3M
Filed 05/14
Traded 05/12
- Daniel Patrick O'Day
Sell10b5-1 planGilead Sciences
Sell10b5-1 planGilead Sciences
GILD
$895.1K
6,950 sh
$895.1K
Filed 04/29
Traded 04/28
